2024-01-25 12:12:13 ET
Summary
- NKTX has seen a significant increase in stock price, recovering from a previous decline following the failure of rival Fate Therapeutics' NK program.
- NKTX's NK cell-based therapies have shown promising results, including a complete remission rate of 60% in patients with acute myeloid leukemia.
- The company's focus on a specific lymphodepletion regimen has shown better safety and durability outcomes, positioning them as a leader in the NK cell therapy space.
I covered Nkarta ( NKTX ) nearly a year ago, when I said that despite producing solid-looking data, the stock seems to be going down due to various reasons, one being Fate’s NK program failure. The stock is now up over 100% since that time, which needs some exploring....
Read the full article on Seeking Alpha
For further details see:
Nkarta: Possible Upside From H1 Update, If Positive